S
Stéphane Ederhy
Researcher at University of Paris
Publications - 168
Citations - 5152
Stéphane Ederhy is an academic researcher from University of Paris. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 26, co-authored 136 publications receiving 3307 citations. Previous affiliations of Stéphane Ederhy include Pierre-and-Marie-Curie University & University of Cambridge.
Papers
More filters
Journal ArticleDOI
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
Stéphane Champiat,Stéphane Champiat,Olivier Lambotte,Emmanuel Barreau,Rakiba Belkhir,Amandine Berdelou,Franck Carbonnel,Cécile Cauquil,Philippe Chanson,Philippe Chanson,Michael Collins,Antoine Durrbach,Stéphane Ederhy,S. Feuillet,Hélène François,Julien Lazarovici,J. Le Pavec,J. Le Pavec,E. De Martin,Christine Mateus,Jean-Marie Michot,Didier Samuel,Jean-Charles Soria,Jean-Charles Soria,Caroline Robert,Alexander M.M. Eggermont,Aurélien Marabelle,Aurélien Marabelle +27 more
TL;DR: Practical guidelines are proposed for the oncologist to help in the clinical care of patients under ICB immunotherapy, which can become life-threatening if not anticipated and managed appropriately.
Journal ArticleDOI
Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor–Related Cardiotoxicity
Marion Escudier,Jennifer Cautela,N. Malissen,Yann Ancedy,Morgane Orabona,Johan Pinto,Sandrine Monestier,Jean-Jacques Grob,Ugo Scemama,Alexis Jacquier,Nathalie Lalevée,Jeremie Barraud,Michael Peyrol,Marc Laine,Laurent Bonello,Franck Paganelli,Ariel Cohen,Fabrice Barlesi,Stéphane Ederhy,Franck Thuny +19 more
TL;DR: The medical records of patients with a clinical suspicion of ICI-related cardiotoxicity were reviewed from the databases of 2 cardio-oncology units between March 2015 and April 2017 and found no specific follow-up had previously been established for patients receiving ICIs during the study period.
Journal ArticleDOI
Management of hypertension in angiogenesis inhibitor-treated patients
Hassane Izzedine,Stéphane Ederhy,François Goldwasser,J-C. Soria,Gérard Milano,A. Cohen,David Khayat,J-P. Spano +7 more
TL;DR: No clear recommendation for an antihypertensive agent can be made in this context because there is a lack of controlled studies addressing the subject.
Journal ArticleDOI
Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer.
Charles Dolladille,Stéphane Ederhy,Marion Sassier,Jennifer Cautela,Franck Thuny,Ariel Cohen,Sophie Fedrizzi,Basile Chrétien,Angélique Da-Silva,Anne-Flore Plane,Damien Legallois,Paul Milliez,Véronique Lelong-Boulouard,Joachim Alexandre +13 more
TL;DR: A 28.8% recurrence rate of the same irAE associated with the discontinuation of ICI therapy after a rechallenge with the same ICI is found in patients with cancer.
Journal ArticleDOI
HIV and coronary heart disease: time for a better understanding.
Franck Boccara,Sylvie Lang,C. Meuleman,Stéphane Ederhy,Murielle Mary-Krause,Murielle Mary-Krause,Dominique Costagliola,Dominique Costagliola,Jacqueline Capeau,Ariel Cohen +9 more
TL;DR: Cardiovascular prevention in HIV-infected patients is a challenge for both cardiologists and physicians involved in HIV care and requires new tools to assess this higher risk and studies to determine whether intensive primary prevention is warranted.